Amedisys (AMED) PT Raised to $133 at RBC Capital
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Price: $100.99 --0%
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Join SI Premium – FREE
RBC Capital analyst Frank Morgan raised the price target on Amedisys (NASDAQ: AMED) to $133.00 (from $126.00) while maintaining a Outperform rating following solid Q4.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Incyte (INCY) PT Raised to $105 at Truist Securities
- Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink
- Definium Therapeutics Inc (DFTX) PT Raised to $52 at Leerink
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
